Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Financing Activities (2016 - 2025)

Regenxbio has reported Cash from Financing Activities over the past 12 years, most recently at -$9.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$9.6 million for Q4 2025, down 23.82% from a year ago — trailing twelve months through Dec 2025 was $116.8 million (up 25.99% YoY), and the annual figure for FY2025 was $116.8 million, up 25.99%.
  • Cash from Financing Activities for Q4 2025 was -$9.6 million at Regenxbio, down from -$7.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for RGNX hit a ceiling of $211.3 million in Q1 2021 and a floor of -$12.0 million in Q4 2023.
  • Median Cash from Financing Activities over the past 5 years was -$7.3 million (2021), compared with a mean of $17.0 million.
  • Peak annual rise in Cash from Financing Activities hit 7552.52% in 2021, while the deepest fall reached 436.27% in 2021.
  • Regenxbio's Cash from Financing Activities stood at -$7.6 million in 2021, then fell by 17.12% to -$8.9 million in 2022, then tumbled by 34.1% to -$12.0 million in 2023, then soared by 35.3% to -$7.7 million in 2024, then decreased by 23.82% to -$9.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$9.6 million (Q4 2025), -$7.1 million (Q3 2025), and $139.2 million (Q2 2025) per Business Quant data.